Merck (MRK) Completes Acquisition of ArQule (ARQL) Jan 16, 2020 08:34AM
Merck Completes Acquisition of ArQule Jan 16, 2020 08:34AM
Merck (MRK) Begins Tender Offer to Acquire ArQule (ARQL) Dec 17, 2019 06:46AM
Merck Begins Tender Offer to Acquire ArQule Dec 17, 2019 06:45AM
Merck (MRK) to Acquire ArQule (ARQL) for $20/Share in $2.7B Deal Dec 9, 2019 06:46AM
View Older Stories

Dec 9, 2019 06:45AM Merck to Acquire ArQule, Advancing Leadership in Oncology
Jun 25, 2018 07:00AM ArQule Added to the Russell 2000® Index
Jun 15, 2018 07:03AM ArQule (ARQL) Provides Results from Ongoing Phase 1 Dose Escalation Study of its Reversible BTK Inhibitor ARQ 531
Jun 15, 2018 07:00AM ArQule Presents Results from Ongoing Phase 1 Dose Escalation Study of its Reversible BTK Inhibitor, ARQ 531
Jun 14, 2018 07:00AM ArQule to Present at The JMP Securities Life Sciences Conference on June 21, 2018
Jun 7, 2018 07:00AM ArQule to Present Clinical Data for its BTK Inhibitor, ARQ 531, at the 23rd Congress of the European Hematology Association (EHA)
May 31, 2018 07:00AM ArQule to Present at the Jefferies 2018 Healthcare Conference on June 7, 2018
May 24, 2018 07:00AM ArQule Strengthens Executive Team with Two Key Appointments
May 7, 2018 07:00AM ArQule Reports First Quarter 2018 Financial Results
Apr 23, 2018 04:35PM ArQule to Report First Quarter 2018 Financial Results on May 7, 2018
Apr 17, 2018 07:00AM ArQule and Basilea Enter into Exclusive License Agreement for Derazantinib in the US, EU, Japan and Rest of World Excluding Greater China
Mar 20, 2018 07:00AM ArQule to Present at the 17th Annual Needham Healthcare Conference on March 27, 2018
Mar 15, 2018 07:00AM ArQule to Present Data at the 2018 American Association for Cancer Research (AACR) Annual Meeting
Mar 5, 2018 07:00AM ArQule Reports Fourth Quarter and Full Year 2017 Financial Results
Mar 5, 2018 06:50AM ArQule to Present at the 30th Annual Roth Conference on March 12, 2018
Feb 20, 2018 07:00AM ArQule To Report Fourth Quarter 2017 Financial Results On March 5, 2018
Feb 8, 2018 07:00AM ArQule to Present at The Leerink Partners 7th Annual Global Healthcare Conference on February 15, 2018
Feb 7, 2018 07:00AM Roivant Sciences and ArQule Enter into License Agreement for Derazantinib in China
Nov 21, 2017 07:09AM ArQule (ARQL) Reports Dosing in Registrational Trial of FGFR Inhibitor, Derazantinib, for Treatment of iCCA
Nov 21, 2017 07:00AM ArQule Announces Dosing in a Registrational Trial of FGFR Inhibitor, Derazantinib, for Treatment of Intrahepatic Cholangiocarcinoma
Nov 9, 2017 07:00AM ArQule Reports Third Quarter 2017 Financial Results
Nov 8, 2017 07:00AM ArQule Announces $9.5 Million Private Placement of Preferred Stock
Nov 1, 2017 07:21AM ArQule (ARQL) Announces FDA Granted Rare Pediatric Disease Designation to its Miransertib for Treatment of Proteus Syndrome
Nov 1, 2017 07:00AM FDA Grants Rare Pediatric Disease Designation to ArQule’s Miransertib (ARQ 092) for the Treatment of Proteus Syndrome
Oct 26, 2017 07:00AM ArQule To Report Third Quarter 2017 Financial Results On November 9, 2017
Oct 16, 2017 07:11AM ArQule (ARQL) Announces $15.7M Private Placement of Common Stock
Oct 16, 2017 07:00AM ArQule Announces $15.7 Million Private Placement of Common Stock
Sep 19, 2017 07:00AM ArQule to Present at the Cantor Fitzgerald Global Healthcare Conference on September 26, 2017
Aug 4, 2017 07:00AM ArQule Reports Second Quarter 2017 Financial Results
Jul 21, 2017 07:00AM ArQule To Report Second Quarter 2017 Financial Results On August 4, 2017
Jul 11, 2017 07:02AM ArQule (ARQL) Says First Patient Dosed in Phase 1 Trial of BTK Inhibitor, ARQ 531
Jul 11, 2017 07:00AM ArQule Announces First Patient Dosed in Phase 1 Trial of BTK Inhibitor, ARQ 531, for B-cell Malignancies
Jun 23, 2017 07:06AM ArQule (ARQL) Presents Preclinical Data for BTK Inhibitor, ARQ 531, at EHA
Jun 23, 2017 07:00AM ArQule Presents Preclinical Data for BTK Inhibitor, ARQ 531, at the 22nd Annual Congress of the European Hematology Association (EHA)
Jun 7, 2017 07:00AM ArQule Announces First Patient Dosed in Company Sponsored Phase 1/2 Trial of AKT Inhibitor, ARQ 092, for Rare Overgrowth Diseases
Jun 5, 2017 05:49AM ArQule (ARQL) Delivers Phase 1/2 Clinical Data with ARQ 087 in Intrahepatic Cholangiocarcinom at ASCO Meetings
Jun 3, 2017 09:00AM ArQule Presents Phase 1/2 Clinical Data with ARQ 087 in Intrahepatic Cholangiocarcinoma at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
May 18, 2017 06:00AM ArQule to Present Preclinical Data for BTK Inhibitor, ARQ 531, at the 22nd Annual Congress of the European Hematology Association (EHA)
May 17, 2017 05:00PM ArQule to Present Clinical Data at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
May 3, 2017 07:00AM Arqule Reports First Quarter 2017 Financial Results
Apr 26, 2017 07:43AM ArQule (ARQL) Receives U.S. Patent Covering Composition of Matter of Proprietary Reversible BTK Inhibitor, ARQ 531
Apr 26, 2017 07:00AM ArQule Announces Issuance of U.S. Patent Covering Composition of Matter of Proprietary Reversible BTK Inhibitor, ARQ 531
Apr 19, 2017 07:00AM ArQule To Report First Quarter 2017 Financial Results On May 3, 2017
Apr 11, 2017 07:04AM ArQule (ARQL) Announces IND Application for BTK Inhibitor ARQ 531 Cleared by FDA
Apr 11, 2017 07:00AM ArQule Receives Clearance of Investigational New Drug Application from the FDA for Proprietary Reversible BTK Inhibitor, ARQ 531
Mar 28, 2017 07:00AM ArQule to Present at the 16th Annual Needham Healthcare Conference on April 4, 2017
Mar 27, 2017 07:01AM ArQule (ARQL) Says Phase 3 Clinical Study of Tivantinib in Hepatocellular Carcinoma in Japan Didn't Meet Primary Endpoint
Mar 27, 2017 07:00AM ArQule Announces Top-Line Results of Phase 3 Clinical Study of Tivantinib in Hepatocellular Carcinoma in Japan
Mar 7, 2017 07:00AM ArQule Reports Fourth Quarter and Full Year 2016 Financial Results
Feb 24, 2017 07:00AM ArQule To Report Fourth Quarter and Year End 2016 Financial Results On March 7, 2017
View Older Stories